Positive data was posted for iclaprim today in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Multi-drig resistant bacteria are common in ABSSSI. Several drugs are being developed for MDR infections. In addition to iclaprim, beta-lactams being developed include cefiderocol, ceftobiprole and sulopenem. Imipenem/cilastatin is also being tested in combination with the carbapenem dehydropeptidase relebactam. New antibiotics also include a systemic dosage of fusidic acid, new tetracyclines eravacycline and omadacycline and the pleuromutilin antibiotic lefamulin. Look for my review of new antibiotics in development for MDR in an upcoming issue of Hospital Pharmacy.
Check out up-to-date information about the these and other drugs in development anytime you want with a subscription to the Prescribe Right Pharmaceutical Pipeline Tracker. Comments are closed.
|
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker Latest Tweets from Prescribe Right
Archives
May 2023
|
Services |
Company |
|
© COPYRIGHT 2015. ALL RIGHTS RESERVED.
|